Celgene, GELA Initiate RELEVANCE Phase III Study In Follicular Lymphoma RTT News The combination of REVLIMID and rituximab, also referred to as the R-squared or R2 regimen pioneered by Nathan Fowler, MD and colleagues at the MD Anderson Cancer Center, Houston TX, would be investigated in a study of up to 1000 patients with newly ... Celgene Unit Releases Final Phase 2 Data Evaluating REVLIMID and Rituximab (CELG) Final Phase II Data Evaluating REVLIMID(R) and Rituximab in Patients with ... Final Phase II Data Evaluating REVLIMID and Rituximab in Patients with ... |
